SCHEMBL987829

SCHEMBL987829

CSCC[C@@H](NC=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
RNPEP Q9H4A4 1/20 0.47
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.43
PKM P14618 1/20 0.42
FNTA P49354 4/20 0.42
FNTB P49356 4/20 0.42
FOLH1 Q04609 1/20 0.41
CA2 P00918 2/20 0.41
MAPK1 P28482 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38594 1.00 ALDH1A1 (0.54) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL28781190 1.00 ALDH1A1 (0.54) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL38595 1.00 ALDH1A1 (0.54) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL28222352 0.98 ALDH1A1 (0.52) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL16149858 0.98 ALDH1A1 (0.52) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL16149859 0.98 ALDH1A1 (0.52) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL28222355 0.98 ALDH1A1 (0.52) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
Fluoride SCHEMBL29174742 0.98 ALDH1A1 (0.52) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL16150979 0.96 ALDH1A1 (0.51) ALDH1A1KDM4EL3MBTL1RNPEPLMNA
SCHEMBL28269388 0.96 ALDH1A1 (0.51) ALDH1A1KDM4EL3MBTL1RNPEPLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119090106-A Real-time ship navigation route planning method based on augmented reality 广州市上赛电子科技有限公司 2024-12-06 CN claimed
US-20240280590-A1 COMPOSITIONS AND METHODS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY BIOMARKER DETECTION UNIVERSITY OF WASHINGTON (US) 2024-08-22 US claimed
CN-110857315-A Polypeptide medicine and derivative for treating tumor and use method thereof 许洋 2020-03-03 CN claimed
CN-122029189-A Anti-SARS-CoV-2 spike (S) antibodies and their use in treatment COVID-19 诺瓦瓦克斯股份有限公司 2026-05-12 CN disclosed
US-12587161-B2 Higher order lamb wave acoustic devices with complementarily-oriented piezoelectric layers THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2026-03-24 US disclosed
CN-121606556-A Treatment of fragile X syndrome with cannabidiol 和谐生物科学管理有限公司 2026-03-06 CN disclosed
EP-3928072-B1 CORE BODY TEMPERATURE SENSOR AND METHOD FOR THE MANUFACTURING THEREOF TNO (NL) 2026-02-11 EP disclosed
US-20260027137-A1 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL HARMONY BIOSCIENCES MANAGEMENT, INC. (US) 2026-01-29 US disclosed
EP-4611738-A1 COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME Lykos Therapeutics, Inc. (US) 2025-09-10 EP disclosed
US-20250177322-A1 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL HARMONY BIOSCIENCES MANAGEMENT, INC. (US) 2025-06-05 US disclosed
CN-119090106-B Real-time ship navigation route planning method based on augmented reality 广州市上赛电子科技有限公司 2025-05-30 CN disclosed
EP-3965730-A1 ANTIBIOTIC ELUTING POLY (ESTER UREA) FILMS FOR INFECTION CONTROL OF IMPLANTABLE MEDICAL DEVICES The University of Akron (US) 2022-03-16 EP disclosed
US-20220073908-A1 METHODS OF PRODUCING HIGH DIVERSITY PEPTIDE LIBRARIES AND PROMOTING PROTEIN FOLDING Repertoire Immune Medicines, Inc. 2022-03-10 US disclosed
CN-110857315-A Polypeptide medicine and derivative for treating tumor and use method thereof 许洋 2020-03-03 CN disclosed
WO-2015164289-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2015-10-29 WO disclosed
US-20110020914-A1 METHODS FOR ENHANCING GROWTH OF ORGANISMS IN AN AQUEOUS GROWTH MEDIUM NOVUS INTERNATIONAL INC (US) 2011-01-27 US disclosed
WO-2010126794-A1 METHODS FOR INCREASING GROWTH AND YIELD OF PLANTS WITH METHIONINE COMPOUNDS NOVUS INTERNATIONAL INC. (US) 2010-11-04 WO disclosed
US-20070231377-A1 COMPOSITIONS FOR PROMOTING HAIR GROWTH NOVUS INTERNATIONAL INC. (US) 2007-10-04 US disclosed
EP-0304021-B1 ACYLAMINO ACID RACEMASE, PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 1993-04-28 EP disclosed
EP-0304021-A2 Acylamino acid racemase, Production and use thereof Takeda Chemical Industries, Ltd. (JP) 1989-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12587161-B2 Higher order lamb wave acoustic devices with complementarily-oriented piezoelectric layers PIEZO1, GJB2, GJA1 ALDH1A1 4222/4885KDM4E 1260/4885L3MBTL1 42/4885
US-20260027137-A1 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL MECP2, FOS, FOSB ALDH1A1 4670/4885KDM4E 59/4885L3MBTL1 1311/4885
US-20070231377-A1 COMPOSITIONS FOR PROMOTING HAIR GROWTH FGF1, MTR, HGF ALDH1A1 2239/4885KDM4E 1133/4885L3MBTL1 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.